



Maelor plc

20 May 2004

Maelor plc Granted Regulatory Approval for ContiSol™ in Canada

Wrexham, UK, 20 May 2004: Maelor plc, the AIM-listed specialist healthcare products company, today announced that ContiSol, its own brand of urethral catheter maintenance solutions, has been approved for use as a medical device in Canada. This regulatory approval marks a major milestone for the Company, being the first time that a Maelor product will be available in North America.

ContiSol is a series of products designed to prolong the life of indwelling urological catheters and to prevent blockages. The range offers an appropriate choice of agents for the management of catheter problems, such as blockages, encrustation, and the formation of sediment, all of which may lead to infection. The container has been designed to enable either medical staff or the patient, through gentle agitation of the solution in the catheter, to achieve optimal dissolution and flushing. ContiSol is designed to reduce the need for frequent catheter change.

Maelor is actively seeking a distribution partner in Canada, and the launch of ContiSol will take place as soon as possible following this appointment. In the meantime, Maelor is collaborating in a multicentre clinical trial co-ordinated by Dr Katherine Moore of the University of Alberta. In this study the use of ContiSol is to be compared with current clinical practice, which is to replace urethral catheters when a blockage occurs.

Maelor Chief Executive Stephen Appelbee said: "Prior to this approval, products such as ContiSol were always considered to be drugs, rather than devices, in North America. Our team's achievement in persuading Health Canada to reverse this ruling is not only important locally, but it may have significant implications elsewhere in the world, particularly in the USA."

ENDS

For further information:

Maelor plc

Stephen Appelbee, Chief Executive Officer 01978 810 153

Financial Dynamics

Ben Atwell/Lucy Briggs 020 7831 3113

Notes to Editors:

Maelor plc

Maelor is an AIM listed specialist healthcare products company. Maelor operates on a virtual basis, outsourcing both product development and manufacturing, and outlicensing the sale of its products to distribution partners.

The company has several products on the market including OptiFlo®, ContiSol and Volplex®. OptiFlo, a urethral catheter maintenance range, launched in the UK in June 1999 and distributed through Bard Limited, has gained a 42% share of the UK community prescription market, which is estimated to have a value of around £5 million per annum.

ContiSol, Maelor's own brand urethral catheter maintenance range, has already been launched in Spain and Greece. The product has also gained approval in Argentina where launch is expected shortly.

Volplex, the company's blood plasma substitute, is used for patients suffering from the effects of trauma, surgery or certain medical conditions which result in hypovolaemia (lower than normal blood volume).

Maelor has various products in its pipeline including micelle propofol, a reformulation of the world's biggest selling general anaesthetic.

Volplex® and ContiSol™ are trademarks of Maelor Pharmaceuticals Limited. OptiFlo® is a Trademark of Bard Limited.